Teladoc Inc Stock News

It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health companies, around two-thirds have lost value this year, while the Nasdaq is up 32%.

Teladoc Health (TDOC 2.16%) hasn't been an easy stock for investors to hold -- its shares are down by a shocking 88% over the last three years. But few would deny that the company has a substantial amount of real value stemming from its extensive telehealth platform and massive base of subscribers.

Like all companies, Teladoc Health (TDOC 2.16%) will need to evolve a lot over the next three years. The days of the telehealth operator's peak hype are now firmly in the past.

The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University in Baltimore, Maryland, and also serves as the chief medical officer at Sesame, an online telehealth platform.

Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health (TDOC 0.64%) and vaccine maker Novavax (NVAX -1.31%) belong in this group: Both have significantly lagged behind the market since 2021.

Teladoc Health, Inc. (NYSE:TDOC ) Piper Sandler 36th Annual Healthcare Conference December 3, 2024 12:30 PM ET Company Participants Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Jess Tassan - Piper Sandler Jess Tassan All right, my name is Jess Tassan, I cover healthcare services at Piper. I'm so excited to be here with the Teladoc tea...

Teladoc Health, Inc. is currently undervalued, trading at 11x forward free cash flow, presenting a compelling investment opportunity despite its dire outlook. The company's strength lies in its scalable virtual healthcare services, with a focus on chronic condition management and international expansion. Stabilizing revenue growth rates to around 1% in 2025 is crucial for Teladoc's valuation an...

Teladoc Health, Inc.'s telehealth model struggles with low utilization despite its potential, leading to consistent operating losses and a declining average revenue per member. New CEO Chuck Divita aims to revitalize Teladoc by enhancing value propositions, cutting costs, and potentially selling or restructuring the Better Help segment. Teladoc's survival hinges on cost-cutting, maintaining int...